TNFSF10 and neoplasm: Using an NSCLC xenograft mouse model, Yan et al. demonstrated an augmented antitumor effect of TRAIL in combination with luteolin compared to single treatments, determined by a decreased tumor volume and an increased fraction of TUNEL-positive cells [46].